Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

BIORA THERAPEUTICS, INC. (PROG) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
10/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/17/2023 4 NEUMANN CLARKE (See Remarks) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 36,183 shares @ $3.14, valued at $113.6k
Granted 210,175 shares @ $0
08/17/2023 4 dEsparbes Eric (CFO) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 40,022 shares @ $3.14, valued at $125.7k
Granted 219,650 shares @ $0
08/17/2023 4 MOHANTY ADITYA P. (CEO) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 117,881 shares @ $3.14, valued at $370.1k
Granted 559,450 shares @ $0
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Investor presentation, Quarterly results
Docs: "Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results NaviCapTM targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJetTM systemic oral delivery platform device development achieved function targets while continuing to exceed bioavailability targets The company strengthened its intellectual property position with additional patents for both platforms Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific",
"THERAPEUTIC PIPELINE PROGRAM PROGRAM INDICATION DESIGN/FEASIBILITY PRECLINICAL CLINICAL TARGETED THERAPEUTICS"
07/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/16/2023 4 Kotzin Brian L. (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Granted 12,500 shares @ $0
Granted 12,500 options to buy @ $4.7, valued at $58.8k
06/16/2023 4 Powell Lynne (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Granted 12,500 shares @ $0
Granted 12,500 options to buy @ $4.7, valued at $58.8k
06/16/2023 4 Alter Jeffrey D. (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Granted 12,500 shares @ $0
Granted 12,500 options to buy @ $4.7, valued at $58.8k
06/16/2023 4 Howe Jill Ann (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Granted 12,500 shares @ $0
Granted 12,500 options to buy @ $4.7, valued at $58.8k
06/13/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/13/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/17/2023 4 dEsparbes Eric (CFO) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 2,807 shares @ $3.35, valued at $9.4k
05/17/2023 4 NEUMANN CLARKE (See Remarks) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 2,368 shares @ $3.35, valued at $7.9k
05/17/2023 4 MOHANTY ADITYA P. (CEO) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 11,249 shares @ $3.35, valued at $37.7k
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2023 4 NEUMANN CLARKE (See Remarks) has filed a Form 4 on BIORA THERAPEUTICS, INC.
Txns: Granted 57,950 shares @ $0
Granted 21,684 shares @ $0
Paid exercise price by delivering 10,683 shares @ $2.56, valued at $27.3k
03/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/13/2023 SC 13D/A Athyrium Opportunities 2020 LP reports a 32.7% stake in Biora Therapeutics, Inc.
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 5.7% stake in Biora Therapeutics, Inc.
02/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/27/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/12/2023 SC 13D/A Athyrium Opportunities 2020 LP reports a 27.8% stake in Biora Therapeutics, Inc.
01/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy